Allergan depression treatment fails studies, shares slip

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Allergy | Botox | Depression | Health | Study